A Critical Examination of Drug Discovery and its Complex Interplay with the Human Body: A Review

Nishchal Maurya, Aryan Verma*, Dheerendra Kumar* and Ayushi

Drug design is the process of creating novel pharmaceuticals by comprehending a biological target, frequently with the use of bioinformatics and computer modelling techniques. Preclinical research, human clinical trials, and obtaining regulatory clearance for commercialization are all steps in the process.

The creation of new drugs has been expedited by high-throughput screening techniques like Computer-Aided Drug Design (CADD). There are seven phases in the process: Preclinical trial testing, clinical trial testing, pharmacogenomic optimisation, lead compound discovery, lead optimisation, disease selection, and target selection. Clinical trials are FDA-regulated research projects in which participants assist in the exploration for answers to medical problems. Market access, therapeutic effect, monetary rewards, and scientific advancement are all possible outcomes of a successful NDA clearance. In order to manage pharmaceuticals, medical devices, and healthcare goods, guarantee product safety, assess adverse occurrences, and inform regulatory decisions, post-marketing surveillance, or PMS, is essential.

Real-world evidence, patient-reported results, and patient-centric methods are anticipated future trends in regulatory decision-making. Pharmacogenomics is used in personalised medicine to investigate genetic variations and medication interactions; drug-food interactions can impact patient health and result in different treatment outcomes.

Published Date: 2024-04-08; Received Date: 2024-03-08